XNYS · Healthcare · Biotechnology
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | -0.52 | -0.80 | -53.85% | $0 | ❌ Miss | -0.97% | -9.06% | — |
| 2026-03-16 | Q4 2025 | -0.53 | -0.45 | +15.09% | $0 | ✅ Beat | +0.18% | -17.58% | +4.86% |
| 2025-11-12 |
| Q3 2025 |
| -0.65 |
| -0.52 |
| +20.00% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.57 | -0.65 | -14.04% | $0 | ❌ Miss | -4.15% | +9.58% | +24.28% |
| 2025-03-20 | Q4 2024 | — | -0.56 | — | $0 | — | -1.49% | -10.41% | -13.75% |
| 2024-08-13 | Q2 2024 | -0.63 | -0.60 | +4.76% | $0 | ✅ Beat | +6.01% | +12.25% | +44.77% |
| 2024-05-14 | Q1 2024 | -0.46 | -0.76 | -65.22% | $0 | ❌ Miss | -2.26% | -10.38% | -15.11% |
Showing last 7 quarters.